This trial will assess a new oral drug's effectiveness and safety in treating Cystic Fibrosis-related lung flare-ups, compared to a placebo.
- Cystic Fibrosis
- Cystic Fibrosis Pulmonary Exacerbation
1 Primary · 0 Secondary · Reporting Duration: Day 7
3 Treatment Groups
ARV-1801/ACG-701 Active Group
1 of 3
ARV-1801(ACG-701) Active Group
1 of 3
1 of 3
80 Total Participants · 3 Treatment Groups
Primary Treatment: ARV-1801/ACG-701 Active Group · Has Placebo Group · Phase 2
Who is running the clinical trial?
Age Any Age · All Participants · 7 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Has the FDA accepted ARV-1801/ACG-701 Active Group for medicinal use?
"The safety of ARV-1801/ACG-701 Active Group was rated a 2, as there is some data to back up its safety but not yet enough evidence supporting its efficacy." - Anonymous Online Contributor
What number of participants has joined this research effort?
"Affirmative. Clinicaltrials.gov reveals that this medical trial, initiated on February 10th 2023, is actively searching for participants. 80 test subjects are needed from 2 healthcare centres." - Anonymous Online Contributor
Are researchers presently recruiting participants for this research project?
"Affirmative, the information on clinicaltrials.gov suggests that this medical experiment is actively seeking participants. The trial was uploaded to the website on February 10th 2023 and revised for accuracy lastly on February 14th of the same year. 80 individuals are needed across 2 sites for successful completion of this investigation." - Anonymous Online Contributor